** Drug developer MAIA Biotechnology's MAIA.A shares plunge 29% to $1.47 premarket
** MAIA late on Monday announced pricing of $30 million public offering
** Co sold 20 million shares at $1.50 apiece, a 27.5% discount to stock's last close
** Offering led by healthcare-dedicated investors alongside existing shareholders - MAIA
** Proceeds will be used to conduct clinical trials and for working capital, general purposes
** Konik Capital Partners was sole book-running manager for offering
** MAIA had 38.7 million outstanding shares as of March 2, according to offering prospectus
** Lone analyst covering MAIA rates it "buy" and has $12.14 PT - data compiled by LSEG
** As of last close, MAIA stock up 35.3% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Comments